December 6, 2004
Par Pharmaceutical Announces Equity Investment in Abrika Pharmaceuticals

Par Pharmaceutical Begins Shipment of Generic K-Dur^®

November 11, 2004
Par Pharmaceutical Named Best Overall Pharmaceutical Products Manufacturer by Healthcare Distribution Management Association

November 3, 2004
Par Pharmaceutical to Present at the CIBC World Markets 15th Annual Healthcare Conference

November 2, 2004
Par Pharmaceutical Statement on Huntingdon Life Sciences

November 1, 2004
Par Pharmaceutical Announces Tentative Approval of Testosterone Gel 1%

October 27, 2004
Par Pharmaceutical Adopts Stockholder Rights Plan

October 25, 2004
Par Pharmaceutical Licenses Generic Calcitonin Nasal Spray from Nastech Pharmaceutical Company Inc.

September 23, 2004
Par Pharmaceutical Receives Tentative Approval of Tramadol Hydrochloride and Acetaminophen Tablets

September 16, 2004
FDA Accepts for Filing Par Pharmaceutical's NDA for Megestrol Acetate Oral Suspension NCD

September 8, 2004
Par Pharmaceutical to Present at the Bear Stearns 17th Annual Healthcare Conference

Par Pharmaceutical Licenses Nitroglycerin Lingual Spray from Novadel Pharma Inc.

August 27, 2004
Par Pharmaceutical Makes Fortune's New "100 Fastest-Growing U.S. Companies" List

August 9, 2004
Par Pharmaceutical Announces Equity Investment in New River Pharmaceuticals Inc.

July 29, 2004
Par Pharmaceutical Begins Shipment of Fluconazole Tablets

July 26, 2004
Par Pharmaceutical Receives Approval to Market Generic Mycostatin®

July 8, 2004
Par Pharmaceutical Comments on Diastat® Litigation

July 7, 2004
Par Pharmaceutical Announces Court Ruling on Latanoprost

June 30, 2004
Par Pharmaceutical Submits NDA for Megestrol Acetate Oral Suspension NCD

June 21, 2004
Par Pharmaceutical Names Shankar Hariharan Chief Scientific Officer

June 10, 2004
Par Pharmaceutical Closes on Acquisition of Kali Labs

June 10, 2004
Par Pharmaceutical Begins Shipment of Ciprofloxacin Tablets

June 4, 2004
Par Pharmaceutical Announces Dismissal of Valeant Appeal

June 2, 2004
Joseph E. Smith Elected to Board of Directors of Par Pharmaceutical Companies, Inc.™

Par Pharmaceutical Finalizes Amoxicillin Pulsys Agreement With Advancis Pharmaceutical

May 26, 2004
Par Pharmaceutical Announces Strategic Alliance with Orchid Chemicals & Pharmaceuticals Ltd.

Pharmaceutical Resources, Inc. Renamed Par Pharmaceutical Companies, Inc.™

May 4, 2004
Par Pharmaceutical Begins Shipment of Generic Glucovance® Tablets

April 22, 2004
Pharmaceutical Resources to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference

April 13, 2004
Pharmaceutical Resources to Acquire Kali Laboratories for $135 Million, Substantially Expanding R&D Capabilities

April 7, 2004
L. William Seidman Elected to Board of Directors of Pharmaceutical Resources, Inc.

April 7, 2004
Pharmaceutical Resources Receives Final Approval to Market Generic Rebetol® Capsules

March 16, 2004
Pharmaceutical Resources to Participate in Wells Fargo Healthcare Securities Conference

March 2, 2004
Par Pharmaceutical Announces Partnership with Advancis to Develop Novel Form of Antibiotic

March 1, 2004
Par Pharmaceutical to Host Conference Call on March 3

February 27, 2004
Pharmaceutical Resources to Present at Lehman Brothers Seventh Annual Global Healthcare Conference

February 23, 2004
Par Pharmaceutical Announces Receipt of Approvable Letter from FDA for Ribavirin Capsules

February 17, 2004
Pharmaceutical Resources to Present at the Smith Barney 4th Annual Specialty Pharmaceuticals Conference

February 12, 2004
Par Pharmaceutical to Market Generic Purinethol® Tablets

January 28, 2004
Pharmaceutical Resources to present at the Merrill Lynch Global Pharmaceutical, Biotechnology, and Medical Device Conference

January 21, 2004
Pharmaceutical Resources to present at the Piper Jaffray Health Care Conference

January 8, 2004
Pharmaceutical Resources to present at the 22nd Annual J. P. Morgan Healthcare Conference

Archived copies of news releases issued since January 2003 are available on line, grouped by year of release: